Materials and methods
Septic shock, septic shock
SEVERE SEPSIS, SECONDARY, SEPTIC SHOCK, SEPTIC SHOCK
This is a randomized, single-blind, placebo-controlled trial. Between January 2017 and December 2018, 325 septic shock patients were recruited from the ICU of the Affiliated Hospital of Guangdong Medical University. Septic shock was diagnosed according to the 2016 international guidelines of severe sepsis and septic shock 2016 [This study was reviewed and was approved by the Medical Ethical Committee of the Affiliated Hospital of Guangdong Medical University (2016-093KT); The Medical Ethics Committee approves the requirement for informed consent; and the study was conducted in accordance with the Helsinki Declaration. Written informed consent was obtained from the patients or the patients’ legally authorized representatives. The patients were randomized 1:1 to receive furosemide and aminophylline or placebo (Flowchart of trial patients. HR: heart rate; CRRT: continuous renal replacement therapy.A total of 109 patients were randomly divided into a control group (The primary outcomes were the Scr, BUN, GFR, Ccr, and urine output on days 3, 7, and 14. The secondary outcomes were the APACHE II score, SOFA, MAP, CVP, hematocrit and albumin on days 3, 7, and 14, as well as the CRRT time, ICU mortality, hospital mortality and 28-day mortality.SPSS 23.0 software is used for data analysis. The primary outcomes (Scr, BUN, GFR, Ccr, and urine output on days 3, 7, and 14.) were data with normal distribution, and 